Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...

A man with memory problems has said he has been able to “live a full life” while taking part in a trial of the drug lecanemab ...

Britain's medicines regulator gave the green light Thursday to a new Alzheimer's drug which has shown to slow progression of the disease, making it Britain's first such licensed treatment.

Lecanemab – a drug shown to slow the progression of Alzheimer’s disease – has been approved for use, but will not be ...

Alzheimer's patients in Britain's state-run health service are unlikely to get access to Eisai and Biogen's new Leqembi drug, ...

In a decision contrary to its European counterpart, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has ...

Nice said the benefits of lecanemab in slowing the condition are ‘just too small to justify the significant cost’.

In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ε4 (ApoE ε4)* ...

Miki Sogi, an analyst from Bernstein, maintained the Buy rating on Eisai Co (ESALF – Research Report). The associated price target is ...

Lecanemab works by binding to amyloid, a protein which builds up in the brains of people living with Alzheimer’s disease.

Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in the US ...